Qilian International Holding Group (Qilian International Holding Group) ROE % Adjusted to Book Value : -52.44% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Qilian International Holding Group ROE % Adjusted to Book Value?

Qilian International Holding Group's ROE % for the quarter that ended in Sep. 2023 was -34.61%. Qilian International Holding Group's PB Ratio for the quarter that ended in Sep. 2023 was 0.66. Qilian International Holding Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -52.44%.

Qilian International Holding Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Qilian International Holding Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qilian International Holding Group ROE % Adjusted to Book Value Chart

Qilian International Holding Group Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

2.96

2.50

-24.61

Qilian International Holding Group Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial								1.12	0.29	4.56	2.13	-52.44

Competitive Comparison of Qilian International Holding Group's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Qilian International Holding Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qilian International Holding Group's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Qilian International Holding Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Qilian International Holding Group's ROE % Adjusted to Book Value falls into.

Qilian International Holding Group ROE % Adjusted to Book Value Calculation

Qilian International Holding Group's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-16.24%	/	0.66
	=	-24.61%

Qilian International Holding Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-34.61%	/	0.66
	=	-52.44%

Qilian International Holding Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Qilian International Holding Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Qilian International Holding Group (Qilian International Holding Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qilian International Holding Group Ltd (NAS:QLI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jiuquan Economic and Technological Development Zone, Gansu Province, Jiuquan, CHN, 735000

Website

http://ir.qlsyy.net

Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.